Alzheimer's disease (AD) is a neurodegenerative disease. It is a type of dementia and it mainly deals with thinking, memory and behavioral aspects. It is a progressive disease, which in course of time damages most sections of the brain. Beta amyloid peptides (Ab) have been recognized as potential biomarkers to monitor AD. The Ab protein is made up of 39-42 amino acids, which are the main components of the plaques found in the AD brain. This beta amyloid is toxic to the neurons and causes degeneration. In order to measure these biomarkers, nanobiosensing techniques are used. Timely monitoring of Ab levels helps in the detection of the irreversible disease called AD. These techniques fall in two categories, viz., in vitro and in vivo. Several techniques like electrochemical techniques, cantilever-based liposome biosensor, ELISA, PET scan, microdialysis, etc., are discussed further in the article. These techniques can prove to be effective methods for quantifying amyloid deposition within specific brain regions.